HRP20192159T1 - Spojevi za liječenje mišićne atrofije kralježnice - Google Patents

Spojevi za liječenje mišićne atrofije kralježnice Download PDF

Info

Publication number
HRP20192159T1
HRP20192159T1 HRP20192159TT HRP20192159T HRP20192159T1 HR P20192159 T1 HRP20192159 T1 HR P20192159T1 HR P20192159T T HRP20192159T T HR P20192159TT HR P20192159 T HRP20192159 T HR P20192159T HR P20192159 T1 HRP20192159 T1 HR P20192159T1
Authority
HR
Croatia
Prior art keywords
pyrido
pyridazin
pyrimidin
methylimidazo
dimethylimidazo
Prior art date
Application number
HRP20192159TT
Other languages
English (en)
Inventor
Hasane Ratni
Luke Green
Nikolai A. Naryshkin
Maria L. Weetall
Original Assignee
F. Hoffmann - La Roche Ag
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20192159(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann - La Roche Ag, Ptc Therapeutics, Inc. filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20192159T1 publication Critical patent/HRP20192159T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (32)

1. Spoj, naznačen time, da je predstavljen formulom (I) u kojoj je R1 vodik ili C1−7−alkil; R2 vodik, cijano, C1−7−alkil, C1−7−haloalkil ili C3−8−cikloalkil; R3 vodik, C1−7−alkil ili C3−8−cikloalkil; A N-heterocikloalkil ili NR12R13, pri čemu N-heterocikloalkil sadrži 1 ili 2 dušikova atoma u prstenu i po izboru je supstituiran s 1, 2, 3 ili 4 supstituenta izabrana od R14; R12 heterocikloalkil koji sadrži 1 dušikov atom u prstenu, pri čemu je heterocikloalkil po izboru supstituiran s 1, 2, 3 ili 4 supstituenta izabrana od R14; R13 vodik, C1−7−alkil ili C3−8−cikloalkil; R14 nezavisno izabran od vodika, C1−7−alkila, amino, amino-C1−7−alkila, C3−8−cikloalkila i heterocikloalkila ili dva R14 zajedno formiraju C1−7−alkilen; pod uvjetom da ako A predstavlja N-heterocikloalkil koji sadrži samo 1 atom dušika u prstenu, tada je najmanje jedan supstituent R14 amino ili amino-C1−7−alkil; i njihove farmaceutski prihvatljive soli.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je R1 vodik ili C1−7−alkil; R2 vodik, cijano, C1−7−alkil, C1−7−haloalkil ili C3−8−cikloalkil; R3 vodik, C1−7−alkil ili C3−8−cikloalkil; A heterocikloalkil koji sadrži 1 ili 2 dušikova atoma u prstenu, pri čemu je N-heterocikloalkil po izboru supstituiran s 1, 2, 3 ili 4 supstituenta izabrana od R14; R14 nezavisno izabran od vodika, C1−7−alkila, amino, amino-C1−7−alkila, C3−8−cikloalkila i heterocikloalkila ili dva R14 zajedno formiraju C1−7−alkilen; pod uvjetom da ako A predstavlja N-heterocikloalkil koji sadrži samo 1 atom dušika u prstenu, tada je najmanje jedan supstituent R14 amino ili amino-C1−7−alkil; i njihove farmaceutski prihvatljive soli.
3. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je R1 C1−7−alkil.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je R1 metil.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je R2 vodik ili C1−7−alkil.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je R2 vodik ili metil.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da je R3 vodik ili metil.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je R14 nezavisno izabran od C1−7−alkila i heterocikloalkila ili time, da dva R14 zajedno formiraju C1−7−alkilen.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, da je R14 nezavisno izabran od metila, etila i pirolidinila ili time, da dva R14 zajedno formiraju etilen.
10. Spoj prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je A , pri čemu je X N ili CH; R4 vodik, C1−7−alkil ili −(CH2)m-NR9R10; R5 vodik ili C1−7−alkil; R6 vodik ili C1−7−alkil; R7 vodik ili C1−7−alkil; R8 vodik ili C1−7−alkil; R9 i R10 su nezavisno izabrani od vodika, C1−7−alkila i C3−8−cikloalkila; n 0, 1 ili 2; m 0, 1, 2 ili 3; ili R4 i R5 zajedno formiraju C1−7−alkilen; ili R4 i R7 zajedno formiraju C1−7−alkilen; ili R5 i R6 zajedno formiraju C2−7−alkilen; ili R5 i R7 zajedno formiraju C1−7−alkilen; ili R5 i R9 zajedno formiraju C1−7−alkilen; ili R7 i R8 zajedno formiraju C2−7−alkilen; ili R7 i R9 zajedno formiraju C1−7−alkilen; ili R9 i R10 zajedno formiraju C2−7−alkilen; pod uvjetom da ako X je CH, onda R4 je −(CH2)m-NR9R10; i pod uvjetom da ako X je N, a R4 je −(CH2)m-NR9R10, onda m je 2 ili 3.
11. Spoj prema patentnom zahtjevu 10, naznačen time, da X je N.
12. Spoj prema bilo kojem od patentnih zahtjeva 10 do 11, naznačen time, da n je 1.
13. Spoj prema bilo kojem od patentnih zahtjeva 10 do 12, naznačen time, da je R4 vodik.
14. Spoj prema bilo kojem od patentnih zahtjeva 10 do 13, naznačen time, da je R7 vodik ili metil.
15. Spoj prema bilo kojem od patentnih zahtjeva 10 do 14, naznačen time, da je R8 vodik.
16. Spoj prema bilo kojem od patentnih zahtjeva 10 do 15, naznačen time, da R5 i R6 zajedno formiraju etilen.
17. Spoj prema bilo kojem od patentnih zahtjeva 10 do 16, naznačen time, da R9 i R10 zajedno formiraju butilen.
18. Spoj prema bilo kojem od patentnih zahtjeva 1 do 17, naznačen time, da je A odabran iz skupine koju čine: pri čemu su R4, R5, R6, R7 i R8 kao što je definirano u bilo kojem od patentnih zahtjeva od 1 do 17 i time, da je R11 vodik ili C1−7−alkil.
19. Spoj prema bilo kojem od patentnih zahtjeva 1 do 18, naznačen time, da je A odabran iz skupine koju čine piperazin-1-il, 1,4-diazepan-1-il, pirolidin-1-il i heksahidropirolo[1,2−a]pirazin-2(1H)-il, od kojih je svaki po izboru supstituiran s 1 ili 2 supstituenta izabrana od R14 kako je definirano prema bilo kojem od patentnih zahtjeva 1 do 33.
20. Spoj prema bilo kojem od patentnih zahtjeva 1 do 19, naznačen time, da je A odabran iz skupine koju čine:
21. Spoj prema bilo kojem od patentnih zahtjeva 1 do 20, naznačen time, da je A odabran iz skupine koju čine:
22. Spoj prema bilo kojem od patentnih zahtjeva 1 do 21, naznačen time, da je odabran iz skupine koju čine: 2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-(4-metilpiperazin-1-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aR)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aS)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aR)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aS)-8a-metil-1,3,4,6,7,8-heksahidropirolo[1,2−a]pirazin-2-il]-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aR)-8a-metil-1,3,4,6,7,8-heksahidropirolo[1,2−a]pirazin-2-il]-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3S,5R)-3,5-dimetilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3S)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3R)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 7-(1,4-diazepan-1-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-[(3S)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-[(3R)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 7-(1,4-diazepan-1-il)-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(3R,5S)-3,5-dimetilpiperazin-1-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aS)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aS)-8a-metil-1,3,4,6,7,8-heksahidropirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aR)-8a-metil-1,3,4,6,7,8-heksahidropirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3R)-3-pirolidin-1-ilpirolidin-1-il]pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-[(3R)-3-pirolidin-1-ilpirolidin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-(3,3-dimetilpiperazin-1-il)pirido[1,2−a]pirimidin-4-on; 7-(3,3-dimetilpiperazin-1-il)-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-9-metil-7-[(3S)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-9-metil-7-[(3R)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3R,5S)-3,5-dimetilpiperazin-1-il]-9-metil-pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-(3,3-dimetilpiperazin-1-il)-9-metil-pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-9-metil-pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3S,5S)-3,5-dimetilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3S)-3-pirolidin-1-ilpirolidin-1-il]pirido[1,2−a]pirimidin-4-on; 2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-[(3S)-3-pirolidin-1-ilpirolidin-1-il]pirido[1,2−a]pirimidin-4-on; 7-[(3S,5S)-3,5-dimetilpiperazin-1-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-[(3S)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)-7-[(3R)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 7-[(3R,5S)-3,5-dimetilpiperazin-1-il]-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-(3,3-dimetilpiperazin-1-il)-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(3S,5S)-3,5-dimetilpiperazin-1-il]-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(3R)-3-etilpiperazin-1-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; i njihove farmaceutski prihvatljive soli.
23. Spoj prema bilo kojem od patentnih zahtjeva 1 do 22, naznačen time, da je odabran iz skupine koju čine: 7-[(8aR)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aS)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aR)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-7-[(3S,5R)-3,5-dimetilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 7-[(3R,5S)-3,5-dimetilpiperazin-1-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-[(8aS)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-9-metil-7-[(3S)-3-metilpiperazin-1-il]pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-9-metil-pirido[1,2−a]pirimidin-4-on; 7-[(3R,5S)-3,5-dimetilpiperazin-1-il]-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; 7-(4,7-diazaspiro[2.5]oktan-7-il)-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on; i njihove farmaceutski prihvatljive soli.
24. Spoj prema patentnom zahtjevu 22 ili 23, naznačen time, da je spoj 7-[(8aR)-3,4,6,7,8,8a-heksahidro-1H-pirolo[1,2−a]pirazin-2-il]-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on ili njegova farmaceutski prihvatljiva sol.
25. Spoj prema patentnom zahtjevu 22 ili 23, naznačen time, da je spoj 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on ili njegova farmaceutski prihvatljiva sol.
26. Spoj prema patentnom zahtjevu 22 ili 23, naznačen time, da je spoj 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on ili njegova farmaceutski prihvatljiva sol.
27. Spoj prema patentnom zahtjevu 22 ili 23, naznačen time, da je spoj 7-(4,7-diazaspiro[2.5]oktan-7-il)-2-(2,8-dimetilimidazo[1,2−b]piridazin-6-il)-9-metil-pirido[1,2−a]pirimidin-4-on ili njegova farmaceutski prihvatljiva sol.
28. Spoj prema patentnom zahtjevu 22 ili 23, naznačen time, da je spoj 7-[(3R,5S)-3,5-dimetilpiperazin-1-il]-9-metil-2-(2-metilimidazo[1,2−b]piridazin-6-il)pirido[1,2−a]pirimidin-4-on ili njegova farmaceutski prihvatljiva sol.
29. Spoj prema patentnom zahtjevu 22 ili 23, naznačen time, da je spoj .
30. Farmaceutski pripravci, naznačeni time, da sadrže spojeve formule (I) prema bilo kojem od patentnih zahtjeva 1 do 29 ili njihove farmaceutski prihvatljive soli i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
31. Prethodno navedeni spojevi formule (I) prema bilo kojem od patentnih zahtjeva 1 do 29 ili njihove farmaceutski prihvatljive soli, naznačeni time, da se upotrebljavaju kao terapeutski aktivne tvari.
32. Spojevi formule (I) prema bilo kojem od patentnih zahtjeva 1 do 29 ili njihove farmaceutski prihvatljive soli, naznačeni time, da se upotrebljavaju u liječenju ili sprečavanju mišićne atrofije kralježnice (SMA – engl. spinal muscular atrophy).
HRP20192159TT 2014-05-15 2019-11-29 Spojevi za liječenje mišićne atrofije kralježnice HRP20192159T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
EP15721701.9A EP3143025B1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy
PCT/EP2015/060343 WO2015173181A1 (en) 2014-05-15 2015-05-11 Compounds for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
HRP20192159T1 true HRP20192159T1 (hr) 2020-02-21

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20230637TT HRP20230637T1 (hr) 2014-05-15 2015-05-11 Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije
HRP20192159TT HRP20192159T1 (hr) 2014-05-15 2019-11-29 Spojevi za liječenje mišićne atrofije kralježnice

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20230637TT HRP20230637T1 (hr) 2014-05-15 2015-05-11 Postupak za proizvodnju spojeva korisnih za liječenje spinalne mišićne atrofije

Country Status (36)

Country Link
US (1) US9969754B2 (hr)
EP (3) EP3143025B1 (hr)
JP (1) JP6236173B2 (hr)
KR (2) KR102256013B1 (hr)
CN (1) CN106459092B (hr)
AR (1) AR100442A1 (hr)
AU (1) AU2015261046C1 (hr)
BR (1) BR112016026205B1 (hr)
CA (1) CA2948561C (hr)
CL (1) CL2016002836A1 (hr)
CR (1) CR20160518A (hr)
DK (1) DK3143025T3 (hr)
EA (2) EA035068B1 (hr)
ES (2) ES2949660T3 (hr)
FR (1) FR21C1039I2 (hr)
HR (2) HRP20230637T1 (hr)
HU (2) HUE046491T2 (hr)
IL (2) IL248653B (hr)
LT (1) LTPA2021010I1 (hr)
MA (2) MA51988A (hr)
MX (1) MX371050B (hr)
MY (1) MY174284A (hr)
NL (1) NL301128I2 (hr)
NO (1) NO2021035I1 (hr)
NZ (1) NZ725008A (hr)
PE (1) PE20170128A1 (hr)
PH (1) PH12016502081A1 (hr)
PL (2) PL3663296T3 (hr)
PT (1) PT3143025T (hr)
RS (1) RS59718B1 (hr)
SG (1) SG11201609497TA (hr)
SI (2) SI3143025T1 (hr)
TW (1) TWI667239B (hr)
UA (1) UA119670C2 (hr)
WO (1) WO2015173181A1 (hr)
ZA (1) ZA201607026B (hr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037123B1 (ru) 2012-02-10 2021-02-09 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
KR20160045063A (ko) 2013-08-19 2016-04-26 에프. 호프만-라 로슈 아게 스크리닝 방법
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
CA2996657A1 (en) * 2015-11-12 2017-05-18 Kathleen Dorothy MCCARTHY Compounds for treating amyotrophic lateral sclerosis
WO2017080967A1 (en) 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
WO2017100726A1 (en) 2015-12-10 2017-06-15 Ptc Therapeutics, Inc. Methods for treatng huntington's disease
WO2017097728A1 (en) 2015-12-10 2017-06-15 F. Hoffmann-La Roche Ag Bridged piperidine derivatives
EP3544435A4 (en) 2016-11-28 2020-11-04 PTC Therapeutics, Inc. RNA SPLICE MODULATION PROCESSES
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
KR20200017476A (ko) 2017-06-14 2020-02-18 피티씨 테라퓨틱스, 인크. Rna 스플라이싱의 변경 방법
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
JP7075484B2 (ja) * 2017-09-22 2022-05-25 エフ．ホフマン－ラ ロシュ アーゲー ７－（４，７－ジアザスピロ［２．５］オクタン－７－イル）－２－（２，８－ジメチルイミダゾ［１，２－ｂ］ピリダジン－６－イル）ピリド［１，２－ａ］ピリミジン－４－オン誘導体の製造方法
CA3078137A1 (en) 2017-10-03 2019-04-11 F. Hoffmann-La Roche Ag New treatment of sma
WO2019191092A1 (en) 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
BR112020026637A2 (pt) 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
EP3814360B1 (en) 2018-06-27 2024-10-02 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
CA3116458C (en) 2018-10-19 2023-12-12 F. Hoffmann-La Roche Ag New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
WO2020249577A1 (en) 2019-06-12 2020-12-17 F. Hoffmann-La Roche Ag New treatment of sma
US20220315607A1 (en) 2019-07-31 2022-10-06 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
IL305203A (en) 2021-03-17 2023-10-01 Hoffmann La Roche New histories of thiazolopyrimidines
KR20230145461A (ko) 2021-03-18 2023-10-17 에프. 호프만-라 로슈 아게 리스디플람의 제조 방법
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
TW202423419A (zh) 2022-10-14 2024-06-16 美商建南德克公司 治療脊髓性肌肉萎縮症之方法
WO2024154148A1 (en) * 2023-01-21 2024-07-25 Harman Finochem Limited Process for preparation of risdiplam, novel intermediates, and process for preparation thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ292806B6 (cs) * 1996-08-06 2003-12-17 Pfizer Inc. Pyrido- nebo pyrimido-6,6- nebo -6,7-bicyklické deriváty, farmaceutické kompozice na jejich bázi
WO2009042907A1 (en) 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
EP2337609B1 (en) * 2008-08-14 2016-08-17 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
USRE47689E1 (en) * 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EA037123B1 (ru) 2012-02-10 2021-02-09 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2878895A1 (en) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
WO2017080967A1 (en) 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
HRP20230637T1 (hr) 2023-09-29
MY174284A (en) 2020-04-01
EP3663296A1 (en) 2020-06-10
IL248653B (en) 2019-11-28
BR112016026205B1 (pt) 2021-12-07
FR21C1039I2 (fr) 2022-09-02
BR112016026205A8 (pt) 2021-07-20
IL248653A0 (en) 2017-01-31
EP4241772A2 (en) 2023-09-13
KR102213740B1 (ko) 2021-02-09
WO2015173181A1 (en) 2015-11-19
EA202090486A3 (ru) 2020-08-31
US9969754B2 (en) 2018-05-15
MA39995B1 (fr) 2019-11-29
TWI667239B (zh) 2019-08-01
CN106459092A (zh) 2017-02-22
AU2015261046A1 (en) 2016-10-27
BR112016026205A2 (pt) 2017-08-15
LTPA2021010I1 (hr) 2021-10-11
PT3143025T (pt) 2019-12-03
PE20170128A1 (es) 2017-03-16
MA51988A (fr) 2021-01-20
EA202090486A2 (ru) 2020-06-30
EA035068B1 (ru) 2020-04-23
SG11201609497TA (en) 2016-12-29
ES2949660T3 (es) 2023-10-02
PL3663296T3 (pl) 2023-08-07
PL3143025T3 (pl) 2020-03-31
HUE046491T2 (hu) 2020-03-30
KR20210014219A (ko) 2021-02-08
EA201692280A1 (ru) 2018-07-31
FR21C1039I1 (hr) 2021-10-15
CL2016002836A1 (es) 2017-04-21
CR20160518A (es) 2017-02-21
AR100442A1 (es) 2016-10-05
NO2021035I1 (no) 2021-09-10
NL301128I2 (nl) 2021-10-25
HUS2100037I1 (hu) 2021-10-28
IL270027B (en) 2020-08-31
KR20170003687A (ko) 2017-01-09
CA2948561A1 (en) 2015-11-19
SI3143025T1 (sl) 2020-01-31
RS59718B1 (sr) 2020-01-31
AU2015261046B2 (en) 2019-04-18
EP4241772A3 (en) 2023-11-15
EP3143025B1 (en) 2019-10-09
SI3663296T1 (sl) 2023-08-31
NL301128I1 (hr) 2021-09-22
EP3143025A1 (en) 2017-03-22
TW201609738A (zh) 2016-03-16
AU2015261046C1 (en) 2019-07-25
MX371050B (es) 2020-01-14
ZA201607026B (en) 2022-05-25
ES2761423T3 (es) 2020-05-19
DK3143025T3 (da) 2019-12-09
CN106459092B (zh) 2019-10-15
MX2016014547A (es) 2017-02-23
NZ725008A (en) 2019-11-29
CA2948561C (en) 2019-10-22
JP6236173B2 (ja) 2017-11-22
JP2017515863A (ja) 2017-06-15
US20170197990A1 (en) 2017-07-13
KR102256013B1 (ko) 2021-05-26
PH12016502081A1 (en) 2017-01-09
EP3663296B1 (en) 2023-05-17
UA119670C2 (uk) 2019-07-25

Similar Documents

Publication Publication Date Title
HRP20192159T1 (hr) Spojevi za liječenje mišićne atrofije kralježnice
IL257587A (en) Compounds for the treatment of lateral amyotrophic sclerosis
HRP20180080T1 (hr) Pirimidopirimidinoni korisni kao inhibitori wee-1 kinaze
HRP20200624T1 (hr) Derivati 2-(2,4,5-supstituiranog-anilino)pirimidina kao modulatori egfr korisni za liječenje raka
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
NZ628186A (en) Compounds for treating spinal muscular atrophy
PH12016501164A1 (en) Heteroaryl substituted nicotinamide compounds
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
HRP20190814T1 (hr) 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-on, njegove soli i postupci uporabe
HRP20170090T1 (hr) Heteroaril supstituirani pirolo[2,3-b]piridini i pirolo[2,3-b]pirimidini kao inhibitori janus kinaze
HRP20190748T1 (hr) Derivati policikličkog amida kao inhibitori cdk9
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2023000782A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
HRP20151071T1 (hr) Spojevi pirolopirimidina kao inhibitori za cdk4/6
MX2019007073A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
NZ604345A (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
NZ751509A (en) Combination therapy with 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
MX352831B (es) Cristales de sal.
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
HK1143810A1 (en) Imidazo [1,2-a] pyrazine compounds for treatment of viral infections such as hepatitis
IL239447B (en) Converted derivatives of tetrahydro[1,2,4]triazolo[alpha-3,4]pyrimidine-5-yl-benzyl and pharmaceutical preparations containing these derivatives
RU2015148189A (ru) ПРОИЗВОДНЫЕ 2-АМИДОПИРИДО[4, 3-d]ПИРИМИДИН-5-ОНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ WEE-1
RU2014151004A (ru) Пирролопиримидоновые и пирролопиридоновые ингибиторы танкиразы
MX2020009586A (es) Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk.